logo
New Research Underscores the Important Role of Value-Based Care (VBC) in Improving Primary Care Access for Traditional Medicare Patients

New Research Underscores the Important Role of Value-Based Care (VBC) in Improving Primary Care Access for Traditional Medicare Patients

Business Wire09-06-2025
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced new research demonstrating the promising role of value-based care (VBC) in maintaining primary care for senior patients when supported by agilon health, a VBC-enablement company. The study was published in the May 2025 issue of Health Affairs Scholar.
'Primary care is foundational for Medicare beneficiaries, especially those with chronic conditions. Despite its importance, many senior patients, particularly ones with Traditional Medicare (TM), have difficulties finding a primary care provider (PCP) and establishing this enormously critical longitudinal relationship,' said Karthik Rao, MD, chief medical officer, agilon health. 'As PCPs play a key role in providing comprehensive care to patients, we wanted to examine the role of VBC in improving primary care access in this population.'
Using claims data, researchers compared two groups of PCPs with TM patients in their panels: one group that received support from agilon health to adopt a VBC model and one group that maintained prevailing payment structures, primarily fee-for-service (FFS). Unlike FFS models that reward volume, VBC incentivizes PCPs to spend more time with patients and focus on their quality of care. The following results were observed in the study:
After shifting to VBC, PCPs saw eight more new TM patients per year compared to the matched cohort of physicians who did not transition to the full-risk model, representing an approximate 35% relative increase in new TM patient volume, a statistically significant finding (P < 0.001).
PCPs shifting to VBC kept their practices open to new TM patients for 0.7 more months per year on average – nearly one full month annually – compared to the other group (P < 0.001), a statistically meaningful increase in availability in the context of shrinking access and PCP workforce shortages nationally.
'This study provides timely, independent validation of agilon health's VBC approach, confirming its role in increasing availability of primary care access for Medicare patients, including TM patients who historically face more limited options,' added Dr. Rao. 'While agilon's model is built around supporting physicians in full-risk arrangements through Medicare Advantage (MA) and ACO REACH contracts, this study shows that our model can have an even greater impact on communities by helping PCPs improve access to care across all of their Medicare patients.'
Study design
Using FFS claims data from 2019 to 2023, researchers compared two groups of PCPs with at least 50 TM patients in their panels: 208 PCPs who received support to adopt a VBC model for TM and MA patients in 2022 ('adopters'), and 3,657 similar PCPs who maintained their existing payment models (FFS) ('nonadopters').
Researchers evaluated changes in two key outcomes between the two groups each year before, during and after VBC adoption. These outcomes included the number of new TM patients seen annually and the number of months each year that physician panels remained open to new TM patients. Researchers used difference-in-differences statistical methods to isolate the effect of joining the VBC model while accounting for other time-based trends. The primary study limitation was the nonexperimental design with a self-selected group of VBC-adopting PCPs.
National trends in primary care and the promising role of VBC
Access to primary care remains insufficient, despite its critical role in the U.S. healthcare system. Many areas are at risk of becoming 'primary care deserts,' and even well-resourced health systems have started restricting the acceptance of new patients, regardless of insurance type. Additionally, a national shortage of PCPs is projected to reach 57,000 by 2040. Compounding the issue, Medicare payments have dropped by 29% since 2001 after adjusting for physician practice costs. In response, some PCPs have been limiting new patient intake for TM beneficiaries.
VBC models offer a promising path forward, leading to high-quality, cost-effective care. The Center for Medicare & Medicaid Innovation (CMMI) recently announced its goal to increase the share of Medicare beneficiaries in two-sided risk models. Unlike traditional FFS models, full-risk VBC arrangements provide PCPs with fixed payments based on patient demographics and complexity. In exchange, PCPs are held accountable for total medical spending and quality of care. These arrangements incentivize PCPs to proactively manage healthcare needs through efficient team-based approaches. By supporting care delivery transformation, it may also expand PCPs' capacity to serve more patients while maintaining high-quality care.
About agilon health
agilon health is the trusted partner empowering physicians to transform health care in our communities. Through our partnerships and purpose-built platform, agilon is accelerating at scale how physician groups and health systems transition to a value-based Total Care Model for their senior patients. agilon provides the technology, people, capital, process, and access to a peer network of 2,200+ primary care physicians that allow its physician partners to maintain their independence and focus on the total health of their most vulnerable patients. Together, agilon and its physician partners are creating the healthcare system we need – one built on the value of care, not the volume of fees. The result: healthier communities and empowered doctors. agilon is the trusted partner in 30 diverse communities and is here to help more of our nation's leading physician groups and health systems have a sustained, thriving future. For more information, visit agilonhealth.com and connect with us on LinkedIn.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Hims & Hers Health Stock Just Dropped
Why Hims & Hers Health Stock Just Dropped

Yahoo

time2 minutes ago

  • Yahoo

Why Hims & Hers Health Stock Just Dropped

Key Points Hims & Hers Health stock missed on earnings last night. The company grew sales 73% and profits tripled, but Wall Street wanted more. Hims & Hers also reported negative free cash flow for the first half of the year. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS), the telehealth company famous for selling Ozempic lookalikes over the internet, is tumbling today, down 6.7% through 10:55 a.m. ET after missing in its second-quarter earnings report last night, on both the top and bottom lines. Heading into the report, analysts forecast Hims & Hers would earn $0.23 per share on $552 million in sales -- but Hims & Hers earned only $0.17 per share, and sales were less than $545 million. Hims & Hers' Q2 earnings But was the news really as bad as it seems? After all, while Hims & Hers "missed" on sales, it did still grow sales 73% year over year. That was twice as fast as it grew subscribers, too (31%), indicating that not only are more customers signing up for the company's services, but they're buying more, too. And while Hims & Hers missed on earnings, too, those earnings per share nearly tripled year over year. Really, the only "bad" number I see in the report concerns free cash flow (FCF). Through the first half of this year, Hims & Hers grew its operating cash flow only 13%, to $90 million (within a couple of percentage points of reported net income). However, the company spent massively on capital expenditures -- more than $100 million -- resulting in negative FCF for the first half of 2025. Investors seem unsure what to make of the news. At one point this morning, the stock had recovered all its losses, and even turned green, before falling back into the red. Is Hims & Hers stock a sell? So how should investors react to this conflicting news? At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more expensive when valued on FCF -- about 103 times. These might be acceptable valuations if earnings were to continue tripling year after year. In fact, though, analysts see profits growing only 13% this year, and perhaps 57% next. For the time being, Hims & Hers stock remains too expensive to buy. Should you buy stock in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy. Why Hims & Hers Health Stock Just Dropped was originally published by The Motley Fool

Akyso Therapeutics Expands Pipeline with New NIH Grant for Buprenorphine Implant Following Successful Phase 1a Trial of Naltrexone Implant
Akyso Therapeutics Expands Pipeline with New NIH Grant for Buprenorphine Implant Following Successful Phase 1a Trial of Naltrexone Implant

Business Wire

time33 minutes ago

  • Business Wire

Akyso Therapeutics Expands Pipeline with New NIH Grant for Buprenorphine Implant Following Successful Phase 1a Trial of Naltrexone Implant

SALISBURY, Md.--(BUSINESS WIRE)-- Akyso Therapeutics, a privately held biotechnology company developing long-acting subcutaneous drug delivery systems, today announced two major milestones: (1) the successful completion of its first-in-human Phase 1a clinical trial of iSTEP-N®, a bioabsorbable extended-release naltrexone implant for opioid use disorder (OUD) engineered to delivery naltrexone for 12 months following a single, simple, in office treatment, and (2) the receipt of $15 million in federal funding from the National Institute on Drug Abuse (NIDA) to develop a parallel12 month buprenorphine-based implant (iSTEP-B®) for OUD. The iSTEP products represent disruptive ultra long acting formulations of both naltrexone and buprenorphine and with them Akyso Therapeutics is poised to capture a large portion of the $3B OUD treatment market in the US. Share Key Highlights: Phase 1a trial demonstrated that the iSTEP-N® implant was well-tolerated with no serious adverse events or implant-related complications. Sustained therapeutic plasma levels of naltrexone were observed for three months following a single implant. Residual Naltrexone content of the implant after 3-months suggests potential for 12-month efficacy. The iSTEP® platform utilizes a proprietary, fully bioabsorbable polymer system that does not require surgical removal. A Phase 1b study in patients with OUD is planned for early 2026 and will include a comparison to Vivitrol®. $15 million NIDA grant awarded for the development of a 6-12-month extended-release buprenorphine implant, iSTEP-B®. 'We are thrilled to share not only the success of our Phase 1a iSTEP-N® trial, but also the launch of our buprenorphine implant program with support from NIDA,' said Steven Cohen, MD, FACS, co-founder and co-CEO of Akyso Therapeutics. 'This expanded funding and validation from the NIH will allow us to pursue our dual-track approach to transforming OUD treatment with both naltrexone and buprenorphine.' Naltrexone and buprenorphine formulations represent over 90 percent of treatment options for OUD in the United States. The iSTEP products represent disruptive ultra long acting formulations of both naltrexone and buprenorphine and with them Akyso Therapeutics is poised to capture a large portion of the $3B OUD treatment market in the US. The new buprenorphine implant project builds directly upon Akyso's iSTEP® platform. iSTEP-B® will use the same bioabsorbable, subcutaneous delivery system as iSTEP-N®, with the goal of delivering therapeutic buprenorphine levels continuously for more than six months. The company plans to follow a similar clinical development pathway, including formulation, CMC analytics, GLP toxicology, and human trials. 'Our goal is to offer patients long-acting, discreet treatments that reduce relapse risk during the most vulnerable stages of recovery,' said Jeffrey Benner, MD, co-founder and co-CEO. 'With iSTEP-N® entering patient trials and iSTEP-B® now funded for development, we are well-positioned to provide scalable, very long acting, implantable therapies for both opioid and alcohol use disorders.' Akyso's iSTEP-N® program is supported in part by NIDA (UH3DA048338). A description of the Phase 1a trial is available on under the identifier NCT06053197. The new iSTEP-B® buprenorphine program is supported by a separate $15 million federal grant (2025–2029). For more information on Akyso Therapeutics or partnership opportunities, please contact:

Seek Labs Maps High-Burden Mosquito-Borne Infectious Diseases with BioSeeker™, Accelerating Therapeutic Discovery for Chikungunya, West Nile Virus, and Zika
Seek Labs Maps High-Burden Mosquito-Borne Infectious Diseases with BioSeeker™, Accelerating Therapeutic Discovery for Chikungunya, West Nile Virus, and Zika

Business Wire

timean hour ago

  • Business Wire

Seek Labs Maps High-Burden Mosquito-Borne Infectious Diseases with BioSeeker™, Accelerating Therapeutic Discovery for Chikungunya, West Nile Virus, and Zika

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of three of the world's most persistent mosquito-borne infectious diseases—Chikungunya, West Nile Virus, and Zika—using its proprietary BioSeeker™ discovery engine. These newly mapped targets represent a critical expansion of the company's Global Disease Atlas and a major step forward in enabling the development of programmable therapeutics with Seek Labs' PTAP™ platform to combat vector-borne disease threats worldwide. By unlocking targets for Chikungunya, West Nile Virus, and Zika, BioSeeker has compressed years of discovery into weeks, paving the way for programmable, pathogen-specific therapeutics that could be deployed when and where they're needed most. BioSeeker Powers Precision Genomics for Programmable Therapeutics BioSeeker™ is Seek Labs' molecular strategist. By scanning thousands of viral and pathogenic genomes, it identifies conserved, high-potential sequences essential to disease survival and replication. These 'genomic weak points' serve as blueprints for Seek Labs' Programmable Target Ablation Platform (PTAP™), which utilizes CRISPR systems to irreversibly disable pathogens with genomic precision. By unlocking targets for Chikungunya, West Nile Virus, and Zika, BioSeeker has compressed years of discovery into weeks, paving the way for programmable, pathogen-specific therapeutics that could be deployed when and where they're needed most. 'Mosquito-borne diseases are among the most complex and under-addressed in global health, spanning diverse pathogens, vectors, and regions with limited therapeutic tools,' said Jared Bauer, CEO of Seek Labs. 'BioSeeker gives us a global vantage point and a tactical advantage: we know where to strike, and we have the tools to do it.' Global Burden and Urgency Mosquito-borne viral diseases infect over 400 million people each year and remain some of the most overlooked threats in global and regional public health: Chikungunya, spread by Aedes mosquitoes, causes chronic joint pain and has resurged in explosive outbreaks across Asia and the Americas. Zika, also Aedes -borne, is linked to birth defects and neurological disorders, particularly devastating in pregnant individuals. West Nile Virus is spread primarily by Culex mosquitoes and, while many cases are asymptomatic, severe neuroinvasive disease can result in encephalitis, paralysis, and death, especially among older adults and immunocompromised individuals. Despite their scale, these diseases have no approved therapeutics in routine use. As vector ranges expand due to shifting climate conditions and urbanization, the window to respond grows narrower and the need for scalable, regionally adaptable solutions is greater. Additionally, recent reports of West Nile Virus in Utah have brought this growing threat even closer to Seek Labs' doorstep, underscoring the importance of local preparedness alongside global response. A Global Call to Partner in Programmable Therapeutics for Chikungunya, West Nile Virus, and Zika With pathogen mapping complete and PTAP guide designs ready for validation, Seek Labs is actively seeking development partners to advance these targets into the next generation of programmable infectious disease therapeutics. The company invites mission-aligned collaborators—including biopharma developers, government agencies, and global health organizations—to accelerate this next phase and help redefine what's possible in mosquito-borne disease control. About Seek Labs At Seek Labs, we don't wait for change—we build it. We're pursuing the breakthroughs the world can't wait for by developing programmable 'seek-and-destroy' therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health. Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges. Forward-Looking Statements and Regulatory Disclaimer This press release includes forward-looking statements about Seek Labs' technologies, development plans, and partnership opportunities. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ. The technologies described are investigational and have not been reviewed or approved by the FDA or any other regulatory authority for clinical or commercial use.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store